Novo Nordisk Revamps Board, FDA OKs Kresladi
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Novo Nordisk appointed Poul Weihrauch, CEO of Mars, as a board observer to strengthen its position in the highly competitive U.S. obesity market, Reuters reported.
- Lars Rebien Sorensen consolidated his leadership role by becoming board chair in addition to chair of the Novo Nordisk Foundation, promising to strengthen the board’s pharmaceutical and commercial expertise after criticizing the previous board for being slow to address U.S. market challenges.
- Novo Nordisk launched its Wegovy pill across multiple cash‑pay channels in January, expanding beyond traditional insurance routes.
- FDA approved Rocket Pharma’s gene therapy Kresladi for severe leukocyte adhesion deficiency type 1, an ultra‑rare disease, after earlier rejection over manufacturing concerns.
- Rocket Pharma will receive an FDA priority review voucher with the approval, which can accelerate future drug approvals.
- Kresladi is expected to be priced at millions of dollars for a one‑time treatment but is not projected to be a major revenue driver due to the disease’s rarity (~1 in a million, ~25 new cases per year).
Why it matters: Novo Nordisk’s board overhaul and cash‑pay Wegovy rollout aim to capture the fast‑growing U.S. obesity market, while Rocket Pharma’s FDA nod secures a priority review voucher that can fast‑track future drugs, even as Kresladi’s ultra‑rare target limits its revenue upside.
